CN108714164A - 连翘叶红茶提取物的用途 - Google Patents
连翘叶红茶提取物的用途 Download PDFInfo
- Publication number
- CN108714164A CN108714164A CN201810744688.2A CN201810744688A CN108714164A CN 108714164 A CN108714164 A CN 108714164A CN 201810744688 A CN201810744688 A CN 201810744688A CN 108714164 A CN108714164 A CN 108714164A
- Authority
- CN
- China
- Prior art keywords
- black tea
- folium forsythia
- tea extract
- fructus forsythiae
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 108
- 235000006468 Thea sinensis Nutrition 0.000 title claims abstract description 102
- 235000020279 black tea Nutrition 0.000 title claims abstract description 102
- 241000555712 Forsythia Species 0.000 title claims abstract description 61
- 239000000284 extract Substances 0.000 title claims abstract description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000012153 distilled water Substances 0.000 claims abstract description 11
- 238000000605 extraction Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims abstract description 10
- 238000010992 reflux Methods 0.000 claims abstract description 10
- 230000006378 damage Effects 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 230000009471 action Effects 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000005493 rutin Nutrition 0.000 claims description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims description 3
- DTOUWTJYUCZJQD-UJERWXFOSA-N Forsythiaside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H](O)[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O1 DTOUWTJYUCZJQD-UJERWXFOSA-N 0.000 claims description 3
- 239000000022 bacteriostatic agent Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims description 3
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims description 3
- 229960004555 rutoside Drugs 0.000 claims description 3
- CPJKKWDCUOOTEW-YJPXFSGGSA-N 4-[(3s,3ar,6r,6ar)-6-(3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenol Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O)=CC=3)[C@@H]2CO1 CPJKKWDCUOOTEW-YJPXFSGGSA-N 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- CPJKKWDCUOOTEW-UHFFFAOYSA-N sylvatesmin Natural products C1=C(OC)C(OC)=CC=C1C1C(COC2C=3C=C(OC)C(O)=CC=3)C2CO1 CPJKKWDCUOOTEW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 abstract description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 37
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 15
- 231100000753 hepatic injury Toxicity 0.000 description 15
- 229960003180 glutathione Drugs 0.000 description 13
- 102000016938 Catalase Human genes 0.000 description 12
- 108010053835 Catalase Proteins 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 12
- 108010012715 Superoxide dismutase Proteins 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000005229 liver cell Anatomy 0.000 description 7
- 238000004064 recycling Methods 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000028527 righting reflex Effects 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 206010003084 Areflexia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001476 alcoholic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 208000007848 Alcoholism Diseases 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 230000002075 anti-alcohol Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036578 sleeping time Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 2
- 229960005250 naloxone hydrochloride Drugs 0.000 description 2
- RGPDIGOSVORSAK-STHHAXOLSA-N naloxone hydrochloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000012984 Aspalathus linearis Nutrition 0.000 description 1
- 240000006914 Aspalathus linearis Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001013248 Eulepidotis folium Species 0.000 description 1
- DTOUWTJYUCZJQD-QJDQKFITSA-N Forsythiaside Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](OCCc3ccc(O)c(O)c3)[C@H](O)[C@@H](O)[C@@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O DTOUWTJYUCZJQD-QJDQKFITSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241001480233 Paragonimus Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000010841 Silybum marianum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- -1 benzyl carbinol glycosides Chemical class 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000021393 food security Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了连翘叶红茶提取物的用途,具体为连翘叶红茶提取物在制备具有解酒作用的产品或在制备对化学性肝损伤具有辅助治疗作用的产品中的应用;所述连翘叶红茶提取物通过如下方法制备得到:将5‑6月份采摘的连翘叶经过摇青、杀青、发酵后烘干制得连翘叶红茶;按料液比1:5~20,取步骤(1)制得的连翘叶红茶适量,加入体积比为0%‑50%的乙醇/蒸馏水溶液,80‑100℃回流提取1~2h,浓缩,干燥即可。
Description
技术领域
本发明涉及中药提取物的制备和应用,具体属于连翘叶红茶提取物的制备和连翘叶红茶提取物在制备解酒作用的产品或对化学性肝损伤有辅助治疗作用的产品中的应用。
背景技术
在山西、河北等地人们常把连翘嫩叶自制成保健茶饮用,自汉代起就被人们当作延年益寿、美容养颜的茶饮,并有“延年翘”、“打老儿茶”、“长寿茶”的美称,康熙年间曾作为贡品。连翘叶茶具有抗氧化、抗衰老、降血脂、抑菌和非特异性免疫应激的作用。2017年12月25日,山西省山西卫生和计划生育委员会和山西省食品药品监督管理局联合公布了连翘叶地方食品安全标准,意味着连翘叶可作为食品和保健食品进行使用。
连翘叶和果实的成分具有一致性,连翘叶子中的一些活性成分如:连翘苷、连翘酯苷和熊果酸的含量比连翘果实中的高。同时研究表明连翘叶茶和连翘叶有相似的化学成分,主要有苯乙醇苷、木脂素和黄酮等形式的多酚成分以及多糖和蛋白成分。
近年来,人们的应酬越来越多,饮酒已成为一种习俗,一种沟通感情的方式,可以给人们带来热情、兴奋、甚至灵感。但是饮酒时常给人带来胃肠不适、恶心呕吐、心神烦乱、头晕目眩等不适症状,甚至因过量饮酒而经常引发各种意外,给社会和人体健康带来各种隐患。长期过量饮酒,还会加重肝脏负担,严种损伤肝脏,造成脂肪肝、酒精肝、肝炎、肝硬化等疾病,而现代医学治疗酒精性肝病目前只有戒酒,对症治疗,并无特效药。
降低体内血中乙醇及其代谢产物的浓度是解酒药物的作用关键,减轻其对各器官的损伤。当前的解酒产品主要在以下两个方面发挥解酒作用。第一,解酒药物抑制酒精的肠胃吸收,加强乙醇在胃肠道首过效应,降低血中乙醇浓度;第二,解酒药物直接作用于肝代谢的酶系,加速乙醇及其代谢产物的消除速率,减轻其对细胞和组织的损害。长期以来,通过化学合成的方法研制解酒护肝药物并未取得大的突破。现有市售具有解酒的产品多以葛根、灵芝、维生素、水飞蓟、五味子、枸杞、枳椇子为主的保健产品多产自美国和日本,产品有胶囊、片剂、茶和功能饮料等剂型,主要功效为解酒保肝。
连翘叶红茶提取物的制备和应用于解酒产品中还未见相关报道。
发明内容
本发明的目的在于提供一种连翘叶红茶提取物的用途,即连翘叶红茶提取物在制备具有解酒作用的产品或在制备对化学性肝损伤具有辅助治疗作用的产品中的应用。
为达到上述目的,本发明提供的技术方案如下:
本发明提供连翘叶红茶提取物在制备具有解酒作用的产品或在制备对化学性肝损伤具有辅助治疗作用的产品中的应用。
所述的产品为药品、保健品或食品。
所述的连翘叶红茶提取物由以下方法制备得到:
(1)将5-6月份采摘的连翘叶经过摇青、杀青、发酵后烘干制得连翘叶红茶;
(2)按料液比1:5~20,取步骤(1)制得的连翘叶红茶适量,加入体积比为0%-50%的乙醇/蒸馏水溶液,80-100℃回流提取1~2h,浓缩,干燥即得连翘叶红茶提取物。该提取物中含有连翘酯苷A、连翘苷、芦丁、连翘脂素成分。
所述的产品由以下方法制备而成:将得到的连翘叶红茶提取物添加辅料防腐剂、香味剂、着色剂、崩解剂、填充剂、润滑剂、粘合剂、调味剂、抑菌剂中的一种或多种制成各片剂、颗粒剂或胶囊。
本发明的有益效果:
本发明制备的连翘叶红茶提取物具有改善饮酒过量后不良反应和缓解由酒精代谢受阻、过度饮酒神经中枢性麻醉引起的醉酒症状的作用;同时对由化学性造成的脂肪肝、酒精肝、肝炎、肝硬化也具有辅助治疗作用。将连翘叶红茶提取物添加辅料可制成具有解酒作用的或在对化学性肝损伤具有辅助治疗作用的药品、保健品或食品。
附图说明
图1连翘叶红茶水提物的HPLC图
图中:1-连翘酯苷A;2-芦丁;3-连翘苷;4-连翘脂素
具体实施方式
下面通过具体实施例对本发明做出进一步详细说明,但不应将此理解为对本发明保护范围的限制。
实施例1-7为连翘叶红茶提取物产品制备实施例。
实施例8-10为连翘叶红茶提取物应用实施例,其中实验用的连翘叶红茶提取物为实施例1制备的连翘叶红茶提取物。
实施例1
将5月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入蒸馏水(料液比1:20),回流提取2h(温度为80-100℃),浓缩,回收蒸馏水(温度为80-100℃),干燥即得连翘叶红茶提取物,然后添加填充剂和淀粉制备成胶囊剂型的产品。
经分析连翘叶红茶提取物中含有连翘酯苷A、连翘苷、芦丁、连翘脂素等成分(见图1)。
实施例2
将6月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入乙醇-蒸馏水(体积比为10%,料液比1:5),回流提取1h(温度为80-100℃),浓缩,回收乙醇(温度为60-70℃),干燥即得连翘叶红茶提取物,添加着色剂、粘合剂制备成颗粒型的产品。
实施例3
将5月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入乙醇-蒸馏水(体积比为20%,料液比1:10),回流提取1h(温度为80-100℃),浓缩,回收乙醇,干燥即得连翘叶红茶提取物,添加崩解剂、填充剂、粘合剂和润滑剂,压片制备成片剂的产品。
实施例4
将6月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入乙醇-蒸馏水(体积比为30%,料液比1:20),回流提取1h(温度为80-100℃),浓缩,回收乙醇,干燥即得连翘叶红茶提取物,添加崩解剂、填充剂、粘合剂和润滑剂,压片制备成片剂的产品。
实施例5
将5月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入乙醇-蒸馏水(体积比为40%,料液比1:5),回流提取1h(温度为80-100℃),浓缩,回收乙醇,干燥即得连翘叶红茶提取物,然后添加抑菌剂、明胶、甘油、水制备成软胶囊剂型的产品。
实施例6
将6月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入乙醇-蒸馏水(体积比为50%,料液比1:15),回流提取1h(温度为80-100℃),浓缩,回收乙醇,干燥即得连翘叶红茶提取物,分别按其与赋形剂重量比为5:1的比例加入赋形剂,制成颗粒剂。
实施例7
将5月份连翘叶进行摇青、杀青、发酵后烘干即得连翘叶红茶。取连翘叶红茶适量,加入乙醇-蒸馏水(体积比为50%,料液比1:20),回流提取1h(温度为80-100℃),浓缩,回收乙醇,干燥即得连翘叶红茶提取物,然后添加崩解剂、填充剂、粘合剂和润滑剂制备成片剂产品。
实施例8连翘叶红茶提取物对小鼠防醉酒效果试验
1.1实验动物:SPF昆明小鼠60只,雌雄各一半,按体重随机分为6组。
1.2分组与处理:随机分为正常组、模型组、阳性对照组(盐酸纳洛酮注射液0.002g,腹腔注射)和红茶高(18g/kg)、中(9g/kg)、低(4.5g/kg)剂量组,共6组。
1.3实施方法:各组提前禁食16h,末次给药后2h,除Z组外其余各组给予相应的50%酒精(20ml/kg),空白对照组给予生理盐水,30min后Y组给予盐酸纳洛酮(腹腔注射,0.002g/kg)。实验过程中密切观察小鼠翻正反射消失和恢复的情况,同时作好记录。醉酒潜伏期:小鼠给予酒精开始到小鼠出现翻正反射消失所用的时间;睡眠时间:小鼠翻正反射消失直到小鼠再次恢复所消耗的时间;醒酒时间:从小鼠给予酒精到小鼠重新恢复的时间差。
1.4实验结果及讨论
表1连翘叶红茶提取物组小鼠不同时间点翻正反射消失的情况(n=10)
注:由于实验过程中各种条件的影响,本表仅列出各组小鼠给酒精后部分时间点小鼠翻正反射消失的只数。
表2连翘叶红茶提取物不同剂量对小鼠醉酒潜伏期、睡眠时间以及醒酒时间的影响(x±SD,n=10)
注:与模型相比,*表示差异显著(P<0.05);**表示差异显著(P<0.01)
给予小鼠酒精1h后摘眼球取血,检测各组小鼠血清ADH活性,研究连翘叶红茶对急性酒精中毒小鼠血清ADH活性的影响。
表3连翘叶红茶提取物对急性酒精中毒小鼠血清ADH的影响(n=10)
注:#表示与正常组相比,有显著性差异(P<0.05);*表示与模型组相比有显著差异(P<0.05)。
实验结果(表1、表2和表3)显示:小鼠连续给予受试物后,与模型组相比,连翘叶红茶给药组能减少小鼠出现翻正反射消失的只数,也可以显著降低小鼠醉酒的睡眠时间和醒酒时间(P<0.05或P<0.01);与模型组相比,血清ADH活性均升高(P<0.05),且以连翘叶红茶提取物高剂量组作用更佳,说明连翘叶红茶提取物有显著解酒功效。
实施例9连翘叶红茶提取物对小鼠急性酒精性肝损伤的保护作用研究
2.1实验动物与分组:取昆明小鼠90只,分为正常组,模型组,阳性对照组(联苯双酯100mg/kg(0.2ml/10g)),红茶低(4.5g/kg)、中(9g/kg)、高(18g/kg)剂量组。
2.2急性酒精性肝损伤模型的建立
正常小鼠每日经口灌胃给予受试样品,模型组和正常组以等量生理盐水代替,阳性对照组小鼠给予联苯双酯100mg/kg(0.2ml/10g)。动物每周称重2次,连续7天,在最后一次灌胃2h后,除正常组外,其余各组均一次性灌胃50%酒精(20ml/kg),正常组以等量生理盐水代替,禁止小鼠食用饲料,但不禁水,16h后摘眼球取血,处死动物,解剖并收集肝脏,进行各项指标的检测及病理组织学检查。
2.3指标检测
血清TG(甘油三酯)、ALT(谷丙转氨酶)、CAT(过氧化氢酶)、GSH(还原型谷胱甘肽),肝脏MDA(丙二醛)、SOD(超氧化物歧化酶)和GSH,脏器系数和肝组织病理学检查。
表4连翘叶红茶对急性酒精肝损伤小鼠血清TG、ALT、CAT、GSH的影响(n=15)
注:#表示与正常组相比,差异明显(P<0.05);*表示与模型组相比差异明显(P<0.05);**表示与模型组相比差异极显著(P<0.01)。
实验结果(表4)显示:与正常组和模型组相比,连翘叶红茶能降低小鼠血清ALT、AST活性和TG含量,红茶高剂量组提高CAT活性(P<0.05)。
表5连翘叶红茶对急性酒精性肝损伤小鼠肝脏MDA、SOD、GSH的影响(n=15)
注:#表示与正常组相比,有显著性差异(P<0.05);*表示与模型组相比具有显著性差异(P<0.05)
实验结果(表5)显示:肝脏GSH活力,红茶中剂量组相比于模型组,GSH活力显著增强,而其余给药组相对于模型组未见显著性差异。肝脏MDA含量,模型组显著上升(与正常组相比P<0.05),红茶高剂量、中剂量组能降低酒精引起的小鼠肝脏MDA含量增多的现象,红茶低剂量组效果微弱(与模型组相比差异不显著)。
表6连翘叶红茶提取物对急性酒精性肝损伤小鼠脏器系数的影响(n=15)
注:#表示与正常组相比,差异明显(P<0.05);*表示与模型组相比差异明显(P<0.05)。
实验结果(表6)显示:对于急性酒精肝损伤,各组小鼠的心、脾、肺系数与正常组相比没有显著性差异。对于肝脏系数,可以看到模型组相比于正常组显著增大(P<0.05),连翘叶红茶组能显著的降低因过量饮酒造成的肝脏肿胀(与模型组相比具有显著性差异,P<0.05)。所以,连翘叶红茶能缓解饮酒过度小鼠肝脏的肿大。
表7急性酒精肝损伤小鼠肝脏组织病理切片结果
备注:+表示病变的程度
实验结果(表7)显示:对于急性酒精肝损伤小鼠肝脏组织,正常小鼠肝脏细胞未见异常,其余组小鼠肝细胞均出现不同程度的肝细胞水样变、脂肪变及肿胀。其中,模型组肝细胞损伤程度大大高于其他组;红茶高剂量组部分小鼠肝细胞未见异常,肝细胞损伤程度也低于红茶中剂量和低剂量组。
2.4实验结论
在本实验条件下,连翘叶红茶提取物通过降低小鼠血清TBIL和MDA含量,升高CAT、GSH、SOD活力对CCl4致小鼠肝损伤产生保护作用。连翘叶红茶对急性酒精中毒小鼠有保护作用,其作用机制与连翘叶红茶增强ADH活性有关,也有可能是因为连翘叶红茶阻止了胃肠粘膜对乙醇的吸收。连翘叶红茶能降低TG和MDA含量,升高CAT、GSH和SOD活力,从而对急性酒精肝损伤小鼠有保护作用。
实施例10连翘叶红茶提取物对CCl4致小鼠肝损伤的保护作用研究
3.1实验动物与分组:取昆明小鼠90只,分为正常组,模型组,阳性对照组,红茶低(4.5g/kg)、中(9g/kg)、高剂量组(18g/kg),每组15只。
3.2急性酒精性肝损伤模型的建立
红茶组每天灌胃给予小鼠相应剂量的水提取物(0.2ml/10g),正常组与模型组以等量生理盐水代替,阳性对照组给予联苯双酯100mg/kg(0.2ml/10g)。连续7天,于最后一次给药后2h,除正常组外,其余各组小鼠都腹腔注射0.1%CCl4(0.1ml/10g),正常组采用同样的方式给予同剂量的生理盐水,禁止小鼠食用饲料,但不禁水,16h后摘眼球取血,处死动物,解剖并收集脏器。
3.3指标检测
血清AST(谷草转氨酶)、ALT(谷丙转氨酶)、CAT(过氧化氢酶)、GSH(还原型谷胱甘肽)和TBIL(总胆红素),肝脏MDA(丙二醛)和SOD(超氧化物歧化酶),脏器系数和肝组织病理学检查。
表8连翘叶红茶对小鼠血清ALT、AST、TBIL、CAT、GSH的影响(n=15)
注:#表示与正常组相比有显著性差异(P<0.05);*表示与模型组相比有显著性差异(P<0.05)。
实验结果(表8)显示:连翘叶红茶高、中、低剂量组ALT、AST、TBIL明显低于模型组(P<0.05),ALT、AST没有表现出明显的量效关系,而TBIL值随剂量的增高而减小(P<0.05);红茶高剂量组GSH明显高于模型组,红茶中剂量和低剂量组虽然与模型组相比未见明显差异,但是有升高GSH的趋势;连翘叶红茶对于小鼠血清CAT的影响不明显,但相对于模型组,连翘叶红茶有升高CAT(P<0.05)的趋势。
表9连翘叶红茶提取物对小鼠肝脏MDA、SOD的影响(n=15)
注:#表示与正常组相比差异显著(P<0.05);*表示与模型组相比差异显著(P<0.05)。
实验结果(表9)显示:连翘叶红茶组小鼠肝脏MDA明显低于模型组(P<0.05);红茶高剂量和红茶中剂量组肝脏SOD活性显著高于模型组(P<0.05),红茶低剂量组与模型组相比没有显著性差异。红茶高剂量、中剂量和低剂量组小鼠肝脏MDA含量、SOD活性未见明显剂量相关性。所以,连翘叶红茶提取物能降低肝损伤小鼠肝脏MDA含量、提高SOD活性,进而对肝脏起到保护作用。
表10连翘叶红茶提取物对小鼠脏器系数的影响(n=15)
实验结果(表10)显示:正常组、模型组与各给药组相比,均没有显示出明显差异(P>0.05)(脏器系数是动物脏器重量与体重的百分比,在一定程度上能反映动物脏器损伤的程度,)。
表11小鼠肝脏病理切片结果
备注:+表示病变的程度
实验结果(表11)显示:除正常组和红茶高剂量组外,其它各组均出现不同程度的肝细胞坏死、炎细胞浸润,其中,模型组较其余三组病变程度重。肝脏组织病理切片结果表明,连翘叶红茶可以有效缓解CCl4引起的小鼠肝脏肝细胞坏死、炎细胞浸润。其中,红茶高剂量组小鼠肝脏肝细胞状态与正常组相似,表现出很好的保护肝损伤的作用。
3.4实验结论
连翘叶红茶提取物可以有效降低CCl4肝损伤小鼠血清ALT和AST活性、TBIL含量,升高CAT、GSH活性以及降低小鼠肝脏MDA含量并且提高SOD活性,从而起到保护肝脏的作用。此外,在实验过程中可以观察到连翘叶红茶组小鼠较模型组活跃,行动敏捷。
Claims (5)
1.连翘叶红茶提取物在制备具有解酒作用的产品或在制备对化学性肝损伤具有辅助治疗作用的产品中的应用。
2.如权利要求1所述的应用,所述的产品为药品、保健品或食品。
3.如权利要求1所述的应用,所述的连翘叶红茶提取物由以下方法制备得到:
(1)将5-6月份采摘的连翘叶经过摇青、杀青、发酵后烘干制得连翘叶红茶;
(2)按料液比1:5~20,取步骤(1)制得的连翘叶红茶适量,加入体积比为0%-50%的乙醇/蒸馏水溶液,80-100℃回流提取1~2h,浓缩,干燥即得连翘叶红茶提取物。
4.如权利要求3所述的应用,所述连翘叶红茶提取物中含有连翘酯苷A、连翘苷、芦丁、连翘脂素成分。
5.如权利要求1所述的应用,所述的产品由以下方法制备而成:将得到的连翘叶红茶提取物添加辅料防腐剂、香味剂、着色剂、崩解剂、填充剂、润滑剂、粘合剂、调味剂、抑菌剂中的一种或多种制成各片剂、颗粒剂或胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810744688.2A CN108714164A (zh) | 2018-07-09 | 2018-07-09 | 连翘叶红茶提取物的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810744688.2A CN108714164A (zh) | 2018-07-09 | 2018-07-09 | 连翘叶红茶提取物的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108714164A true CN108714164A (zh) | 2018-10-30 |
Family
ID=63914026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810744688.2A Pending CN108714164A (zh) | 2018-07-09 | 2018-07-09 | 连翘叶红茶提取物的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108714164A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110583833A (zh) * | 2019-10-31 | 2019-12-20 | 山西省医药与生命科学研究院 | 一种连翘红茶速溶茶及其制备方法 |
CN113455572A (zh) * | 2021-08-04 | 2021-10-01 | 中国科学院过程工程研究所 | 一种连翘叶速溶茶及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912019A (zh) * | 2010-08-11 | 2010-12-15 | 左权县馨源丰商贸有限公司 | 红茶型连翘叶保健茶 |
-
2018
- 2018-07-09 CN CN201810744688.2A patent/CN108714164A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101912019A (zh) * | 2010-08-11 | 2010-12-15 | 左权县馨源丰商贸有限公司 | 红茶型连翘叶保健茶 |
Non-Patent Citations (4)
Title |
---|
无: "红茶含糖高 解酒效果好", 《医药保健杂志》 * |
杨建雄等: "连翘叶茶保肝作用的实验研究", 《陕西师范大学学报(自然科学版)》 * |
王本祥: "《现代中药药理与临床》", 30 June 2004, 天津科技翻译出版公司 * |
韩碧群等: "中国别样茶的整理研究", 《中国现代中药》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110583833A (zh) * | 2019-10-31 | 2019-12-20 | 山西省医药与生命科学研究院 | 一种连翘红茶速溶茶及其制备方法 |
CN113455572A (zh) * | 2021-08-04 | 2021-10-01 | 中国科学院过程工程研究所 | 一种连翘叶速溶茶及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
CN107981324A (zh) | 姜黄发酵食品及其制备方法 | |
CN105395919A (zh) | 一种含有黑木耳提取物、具有降血脂作用的组合物及其制备方法 | |
CN107951935A (zh) | 一种葛根枳椇子破壁组合物及其制备方法和应用 | |
CN103191214B (zh) | 一种解酒护肝制剂 | |
CN110897147A (zh) | 铁皮石斛解酒保肝组合物和制法 | |
KR20110139548A (ko) | 가시오가피를 함유한 숙취 해소 및 간기능 개선용 생약조성물 및 그 제조방법 | |
KR20140040610A (ko) | 발효 청미래덩굴 잎, 이의 제조방법 및 이의 용도 | |
CN108714164A (zh) | 连翘叶红茶提取物的用途 | |
CN101224232A (zh) | 葛根总黄酮在防治酒精性肝损伤和肠道损伤中的应用 | |
CN104523742B (zh) | 一种具有护肝和提高免疫作用的多糖组合物及其应用 | |
CN101961367A (zh) | 一种预防酒精性肝损伤的中药组合物 | |
CN106138101A (zh) | 一种鸡胚胎提取物的制备方法 | |
CN111418850B (zh) | 一种解酒保肝组合物及其制备方法 | |
CN105582033A (zh) | 防治非酒精性脂肪肝病的含化合物k强化的红参浓缩物的药物组合物和保健功能食品 | |
CN106581592A (zh) | 姜黄提取物在制备预防醉酒、解酒及对化学性肝损伤有辅助作用产品中的应用 | |
CN111357982A (zh) | 沙棘复合发酵液及其制备方法、保健饮品、植物酵素 | |
CN109925445A (zh) | 金线莲提取物在制备预防和/或治疗d-氨基半乳糖致小鼠急性肝损伤药物中的应用 | |
CN107669733B (zh) | 用以改善酒精中毒的中草药复方组合物及其用途 | |
CN105012826A (zh) | 一种益智叶提取物及其制备方法、应用 | |
CN101503721B (zh) | 一种蚌肉多糖的提取方法 | |
CN107266599A (zh) | 金针菇多糖、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
CN114009795A (zh) | 一种保护肝脏的大鲵肽营养组合物 | |
CN112717035A (zh) | 一种解酒护肝的中药组合物及其制备方法、应用 | |
CN112007092A (zh) | 一种解酒组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181030 |
|
RJ01 | Rejection of invention patent application after publication |